$29.24
0[0.00%]
At close: Apr 15
$29.24
0[0.00%]
PreMarket: 4:20PM EDT
Twist Bioscience
(NASDAQ:TWST)Twist Bioscience Stock (NASDAQ:TWST), Analyst Ratings, Price Targets, Predictions
Twist Bioscience Corp has a consensus price target of $30.22, established from looking at the 32 latest analyst ratings. The last 3 analyst ratings were released from Barclays, Scotiabank, and Barclays on April 10, 2024, February 5, 2024, and January 25, 2024. With an average price target of $42.67 between Barclays, Scotiabank, and Barclays, there's an implied 45.92% upside for Twist Bioscience Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Scotiabank
Goldman Sachs
Berenberg
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Twist Bioscience
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | TWST | Buy Now | Twist Bioscience | $29.24 | 36.8% | Barclays | Luke Sergott | $45 → $40 | Maintains | Overweight | Get Alert |
| 02/05/2024 | TWST | Buy Now | Twist Bioscience | $29.24 | 47.06% | Scotiabank | Sung Ji Nam | $30 → $43 | Maintains | Sector Outperform | Get Alert |
| 01/25/2024 | TWST | Buy Now | Twist Bioscience | $29.24 | 53.9% | Barclays | Luke Sergott | $30 → $45 | Maintains | Overweight | Get Alert |
| 01/18/2024 | TWST | Buy Now | Twist Bioscience | $29.24 | 53.9% | Goldman Sachs | Matthew Sykes | $25 → $45 | Maintains | Buy | Get Alert |
| 01/17/2024 | TWST | Buy Now | Twist Bioscience | $29.24 | 53.9% | Goldman Sachs | Matthew Sykes | $25 → $45 | Upgrade | Neutral → Buy | Get Alert |
| 09/27/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -7.66% | Berenberg | Gaurav Goparaju | → $27 | Initiates | → Buy | Get Alert |
| 08/07/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -11.08% | Barclays | Luke Sergott | $20 → $26 | Maintains | Overweight | Get Alert |
| 07/13/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -31.6% | Goldman Sachs | Matthew Sykes | $18 → $20 | Maintains | Neutral | Get Alert |
| 05/08/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -38.44% | Baird | Catherine Ramsey | $29 → $18 | Maintains | Outperform | Get Alert |
| 05/08/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -31.6% | Barclays | Luke Sergott | $32 → $20 | Maintains | Overweight | Get Alert |
| 04/19/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -31.6% | Goldman Sachs | Matthew Sykes | $43 → $20 | Maintains | Neutral | Get Alert |
| 04/18/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -31.6% | Goldman Sachs | Matthew Sykes | $43 → $20 | Maintains | Neutral | Get Alert |
| 02/06/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | 47.06% | Goldman Sachs | Matthew Sykes | $50 → $43 | Maintains | Neutral | Get Alert |
| 02/06/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | -0.82% | Baird | Catherine Ramsey | $33 → $29 | Maintains | Outperform | Get Alert |
| 02/06/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | 9.44% | Barclays | Luke Sergott | $37 → $32 | Maintains | Overweight | Get Alert |
| 01/30/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | 26.54% | Barclays | Luke Sergott | $43 → $37 | Maintains | Overweight | Get Alert |
| 01/05/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | 12.86% | Scotiabank | Sung Ji Nam | → $33 | Initiates | → Sector Outperform | Get Alert |
| 01/03/2023 | TWST | Buy Now | Twist Bioscience | $29.24 | 23.12% | Evercore ISI Group | Vijay Kumar | $28 → $36 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2022 | TWST | Buy Now | Twist Bioscience | $29.24 | 12.86% | Baird | Catherine Schulte | $56 → $33 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Twist Bioscience (TWST)?
The latest price target for Twist Bioscience (NASDAQ: TWST) was reported by Barclays on April 10, 2024. The analyst firm set a price target for $40.00 expecting TWST to rise to within 12 months (a possible 36.80% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Twist Bioscience (TWST)?
The latest analyst rating for Twist Bioscience (NASDAQ: TWST) was provided by Barclays, and Twist Bioscience maintained their overweight rating.
When was the last upgrade for Twist Bioscience (TWST)?
The last upgrade for Twist Bioscience Corp happened on January 17, 2024 when Goldman Sachs raised their price target to $45. Goldman Sachs previously had a neutral for Twist Bioscience Corp.
When was the last downgrade for Twist Bioscience (TWST)?
There is no last downgrade for Twist Bioscience.
When is the next analyst rating going to be posted or updated for Twist Bioscience (TWST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Twist Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Twist Bioscience was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating Twist Bioscience (TWST) correct?
While ratings are subjective and will change, the latest Twist Bioscience (TWST) rating was a maintained with a price target of $45.00 to $40.00. The current price Twist Bioscience (TWST) is trading at is $29.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.